Related Experiment Video
Updated: Jul 7, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement
Machteld M Vellinga1, Raoul D Oude Engberink, Alexandra Seewann
1Department of Neurology, University Medical Centre, Amsterdam, The Netherlands. m.vellinga@vumc.nl
Abstract:
Gadolinium-DTPA (Gd-DTPA) is routinely used as a marker for inflammation in MRI to visualize breakdown of the blood-brain barrier (BBB) in multiple sclerosis. Recent data suggest that ultra-small superparamagnetic particles of iron oxide (USPIO) can be used to visualize cellular infiltration, another aspect of inflammation. This project aimed to compare the novel USPIO particle SHU555C to the longitudinal pattern of Gd-DTPA enhancement in multiple sclerosis. Nineteen relapsing-remitting patients were screened monthly using Gd-enhanced MRI. In case of new enhancing lesions, USPIO were injected and 24 h later, MRI was performed and blood was collected to confirm USPIO loading of circulating monocytes. Lesion development was monitored by 3 monthly Gd-DTPA-enhanced scans and a final scan 7-11 months after injection. USPIO-enhancement was observed as hyperintensity on T1-weighted images, whereas no signal changes were observed on T2-weighted-gradient-echo images. In 14 patients with disease activity, 188 USPIO-positive lesions were seen, 144 of which were Gd-negative. By contrast, there were a total of 59 Gd-positive lesions, 15 of which were USPIO negative. Three patterns of USPIO-enhancement were seen: (i) focal enhancement; (ii) ring-like enhancement and (iii) return to isointensity of a previously hypointense lesion. The latter pattern was most frequently observed for lesions that turned out to be transiently hypointense on follow-up scans, and ring-enhancing lesions were less likely to evolve into black holes at follow-up than lesions without ring-like USPIO-enhancement; we speculate this to be associated with repair. In 4% of the USPIO-positive/Gd negative lesions, USPIO-enhancement preceded Gd-enhancement by 1 month. USPIO-enhancement remained visible for up to 3 months in 1.5% of all USPIO-positive lesions. In 29% of the lesions enhancing with both contrast agents, USPIO-enhancement persisted whereas Gd-enhancement had already resolved. In conclusion, the new nano-particle SHU555C provides complementary information to Gd-enhanced MRI, probably related to monocyte infiltration. The use of USPIO-enhanced MRI is likely to lead to more insight in the pluriformity of inflammation in multiple sclerosis.
Insights
Ultra-small superparamagnetic particles of iron oxide (USPIO) offer new insights into multiple sclerosis inflammation, detecting more lesions than traditional Gadolinium-DTPA (Gd-DTPA) contrast agents. This novel nanoparticle, SHU555C, reveals cellular infiltration, complementing MRI assessments of blood-brain barrier breakdown.
Area of Science:
- Neuroimaging
- Radiology
- Nanomedicine
Background:
- Gadolinium-DTPA (Gd-DTPA) is a standard MRI contrast agent for visualizing blood-brain barrier (BBB) breakdown in multiple sclerosis (MS).
- Ultra-small superparamagnetic particles of iron oxide (USPIO) show potential for detecting cellular infiltration, a key aspect of neuroinflammation.
Purpose of the Study:
- To compare the novel USPIO particle SHU555C with Gd-DTPA for longitudinal assessment of inflammation in relapsing-remitting multiple sclerosis.
- To evaluate USPIO's ability to detect inflammatory lesions not visualized by Gd-DTPA.
Main Methods:
- Nineteen relapsing-remitting MS patients underwent monthly Gd-DTPA enhanced MRI.
- USPIO (SHU555C) was administered upon detection of new enhancing lesions, with subsequent MRI and blood collection to assess monocyte loading.
- Lesion evolution was tracked with serial Gd-DTPA scans and a final scan 7-11 months post-injection.
Main Results:
- USPIO detected 188 positive lesions in 14 patients, with 144 (76.6%) being Gd-negative.
- Gd-DTPA identified 59 lesions, 15 (25.4%) of which were USPIO-negative.
- USPIO enhancement patterns included focal, ring-like, and resolution of hypointensity, with ring-like lesions less likely to progress to "black holes."
- USPIO enhancement preceded Gd-enhancement in 4% of lesions and persisted longer than Gd-enhancement in 29% of co-enhancing lesions.
Conclusions:
- The USPIO nanoparticle SHU555C provides complementary information to Gd-DTPA enhanced MRI in multiple sclerosis.
- USPIO-enhanced MRI likely visualizes monocyte infiltration, offering deeper insights into the heterogeneity of MS inflammation.
- This novel imaging approach may enhance understanding of MS pathogenesis and lesion evolution.
More Related Videos
07:15In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis
Published on: October 20, 2013
08:05Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
Published on: March 1, 2017